Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
Jensa Morris, Director of Smilow Hospitalist Service at Yale New Haven Hospital, shared a post on LinkedIn about a recent article by Youssef Saklawi et al, published in Journal of Hospital Medicine, adding:
“There are so many clinical interventions that we do reflexively despite a mountain of clinical evidence to the contrary.
Thank you Journal of Hospital Medicine and TWDFNR for reminding us that LMWH and not UFH should be first choice for patients requiring non-oral treatment for VTE, even for those who may later require thrombolysis or thrombectomy.”
Title: Things we do for no reason™: Routine use of unfractionated heparin for initial anticoagulation in venous thromboembolism
Authors: Youssef Saklawi, Mohamad Ali Tfaily, Bhargav Marthambadi, Adrian Umpierrez
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!